Top Markets
#1 Helium Helium +94.28%
#2 MowCat MowCat +80.93%
#3 Seeker Seeker +59.15%
#4 UnifAI Network UnifAI Network +34.35%
#5 Tensor Tensor +31.21%
#6 TENDIES TENDIES +26.57%
#7 AI XOVIA AI XOVIA +24.77%
#8 Pons Pons +24.26%
#9 Zylo Ecosystem Zylo Ecosystem +21.75%
#10 Bounce Bounce +18.99%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
Rank in Stocks #11443
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Share Price
$8.74
Last synced: 2026-08-28
Market Cap
$699.74M
Change (1 day)
-4.85%
Change (1 year)
-2.29%
Country
US
Trade BridgeBio Oncology Therapeutics Inc. (BBOT)

Category

Healthcare
Operating Margin for BridgeBio Oncology Therapeutics Inc. (BBOT)
Operating Margin as of 2026 TTM: 0.00%
According to BridgeBio Oncology Therapeutics Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for BridgeBio Oncology Therapeutics Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.